FINWIRES · TerminalLIVE
FINWIRES

Alkermes' Orexin May Have Applicability Outside Sleep, RBC Says

By

Alkermes' (ALKS) work on developing applications for orexin agonists outside of sleep indications can reposition the firm as a leader in the space, RBC Capital Markets said in a Monday note.

As orexin in sleep become ever more crowded, the report said interest in other applications build. RBC analysts project a 50/50 split across the base business and future pipeline.

"While there may be potential in at least 5 major disorders, we see the strongest support for ADHD and addiction," they said.

Alkermes is studying orexin applications for ADHD and fatigue, with initial ADHD data expected in Q4, according to the note.

"We think near-term data catalysts for these programs can help investors reframe ALKS as a leader in the space," the note said.

RBC raised its price target to $56 from $45 while maintaining its outperform rating.

Price: $43.13, Change: $+0.68, Percent Change: +1.61%

Related Articles

Wire

Mission Produce Fiscal Q2 Adjusted Earnings, Revenue Fall; Shares Drop After Hours

Mission Produce (AVO) reported fiscal Q2 non-GAAP net income late Monday of $0.01 per diluted share, down from $0.12 a year earlier.Three analysts polled by FactSet expected $0.05.Revenue in the three months ended April 30 fell to $290.9 million from $380.3 million a year earlier.Three analysts expected $256.3 million.The board approved a stock repurchase program of up to $100 million over the next 36 months.The company's shares fell 5.9% in after-hours trading.

$AVO
Wire

Mama's Creations Fiscal Q1 Earnings, Revenue Rise

Mama's Creations (MAMA) reported fiscal Q1 earnings late Monday of $0.05 per diluted share, up from $0.03 a year earlier.Analysts polled by FactSet expected $0.03.Revenue in the three months ended April 30 rose to $52.8 million from $35.3 million a year earlier.Analysts expected $51.6 million.The company's shares fell 2.6% in after-hours trading.

$MAMA
Wire

Tango Therapeutics Launches $500 Million Stock Offering

Tango Therapeutics (TNGX) said Monday it is launching $500 million underwritten public offering of common stock.All shares are offered by the company, according to a statement.Tango said it will grant underwriters a 30-day option to purchase up to an additional $75 million of shares.

$TNGX